Cisatracurium in a myasthenic patient undergoing thymectomy.
OBJECTIVE
The report investigates cisatracurium neuromuscular block in a myasthenic patient undergoing thymectomy.


METHODS
A myasthenic patient (Osserman II B) was prepared preoperatively with 240 mg x day(-1) pyridostigmine. The neuromuscular block produced by 0.05 mg x kg(-1) cisatracurium was monitored by Datex electromyography. The electromyographic response was compared with that in a control group of five non-myasthenic patients. In the myasthenic patient, cisatracurium resulted in a rapid onset of complete (97-98%) neuromuscular block, while a slow onset of partial (80-90%) block was achieved in the control group. Also, administration of 0.05 mg x kg(-1) neostigmine at the end of surgery reversed the neuromuscular block of cisatracurium in the non-myasthenic patients, but did not change the rate of spontaneous recovery in the myasthenic patient.


CONCLUSIONS
The myasthenic patient is sensitive to cisatracurium, as evidenced by a more rapid onset and more marked neuromuscular block compared with the control non-myasthenic patients. This may be attributed to the decreased number of functional endplate acetylcholine receptors in the myasthenic patient, with a consequent decrease of the safety margin of neuromuscular transmission. Also, in contrast with the control group, the rate of recovery from neuromuscular block in the myasthenic patient was not enhanced by neostigmine at the end of surgery. This may be attributed to the prior inhibition of acetylcholinesterase by the preoperative pyridostigmine, as well as by possible desensitization of the cholinergic receptors secondary to prolonged pyridostigmine therapy.
Baraka
A
A
Department of Anesthesiology, American University of Beirut, Lebanon. abaraka@aub.edu.lb
Siddik
S
S
Kawkabani
N
N
D000328:Adult; D000768:Anesthesia, General; D001279:Atracurium; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004558:Electric Stimulation; D004576:Electromyography; D005260:Female; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000628:therapy*; D009388:Neostigmine / Q000627:therapeutic use; D003473:Neuromuscular Nondepolarizing Agents; D011292:Premedication; D011729:Pyridostigmine Bromide / Q000009:adverse effects; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D013934:Thymectomy
D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D009388:Neostigmine; D011729:Pyridostigmine Bromide